Results: 15

Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy: Trends and perspectives

Medicina (B.Aires); 78 (1), 2018
Hepatocellular carcinoma (HCC) is the second cause of cancer-related death in the world and is the main cause of death in cirrhotic patients. Unfortunately, the incidence of HCC has grown significantly in the last decade. Curative treatments such as surgery, liver transplantation or percutaneous ablation...

Immunotherapy-induced pneumonitis: cases report

Einstein (Säo Paulo); 16 (2), 2018
ABSTRACT Immunotherapy-induced pneumonitis is a rare complication with incidence estimated around 3%. This disease is difficult to diagnose and has great morbidity. For this reason, it became a challenge for oncologists and emergencists. We reviewed the case of five patients who used anti-PD1 (program ce...

Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model

Acta cir. bras; 32 (12), 2017
Abstract Purpose: To evaluate the efficacy of nivolumab and comparison with dacarbazine (DTIC) on peritoneal carcinomatosis of malignant melanoma in mouse model. Methods: Mouse skin melanoma cells was injected under the capsule of the peritoneal surface in the left side of the abdomen. On postoperativ...

Cancer immunology and melanoma immunotherapy

An. bras. dermatol; 92 (6), 2017
Abstract: The stimulation of the immune system, in order to generate an attack against cancer cells, similarly to that which occurs in infectious disease, has long been matter of interest in oncology; however, only limited success has been achieved, with different treatment strategies tested in recent ye...

Nuevas posibilidades terapéuticas en melanoma metastásico
Novel therapeutics possibilities for metastatic melanoma

El melanoma ha experimentado un aumento constante en su tasa de incidencia en las últimas cinco décadas a nivel mundial. El pronóstico del paciente con melanoma se relaciona con el estadio de la enfermedad al momento del diagnóstico, con una sobrevida global media de 6,2 meses en pacientes con melano...